OptimizeRx (OPRX) Stock Price, News & Analysis

Company Overview

OptimizeRx, Inc. is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations. These tools allow pharmaceutical and biotechnology firms to deliver personalized messaging to physicians and care teams, ensuring that relevant formulary and financial support information is accessible at the moment of treatment. In addition, OptimizeRx provides data analytics and reporting capabilities that enable clients to measure the impact of their digital outreach and refine strategies to drive prescription growth and patient outcomes.

Founded in 2003 and headquartered in Cleveland, Ohio, OptimizeRx has formed partnerships with a broad spectrum of EHR vendors and health systems across the United States. The company’s network reaches tens of thousands of healthcare providers, making it one of the largest point-of-care communication platforms in the country. OptimizeRx collaborates closely with payers to integrate eligibility and benefit information, ensuring that savings offers and coverage details are accurate and up to date.

OptimizeRx is led by Chief Executive Officer David Whitlinger, who joined the company in 2019 and has overseen its expansion of digital service offerings and strategic alliances. Under his leadership, the company has focused on enhancing interoperability, scaling its network footprint and delivering advanced analytics to clients. While its primary market remains the U.S., OptimizeRx continues to explore opportunities to extend its digital health network into new regions and therapeutic areas.

Key Stats

• Today's Range: $6.25 to $6.55
• 50-Day Range: $4.54 to $6.63
• 52-Week Range: $4.54 to $22.25
• Volume: 366,489 shs
• Average Volume: 462,093 shs
• Market Capitalization: $118.00 million
• P/E Ratio: 17.97
• Dividend Yield: N/A
• Price Target: $13.43
• Consensus Rating: Moderate Buy

OptimizeRx Stock Analysis - MarketRank™

OptimizeRx scored higher than 81% of companies evaluated by MarketBeat, and ranked 191st out of 627 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

OptimizeRx has a consensus price target of $13.43, representing about 113.5% upside from its current price of $6.29.

Amount of Analyst Coverage

OptimizeRx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 17.65%

Earnings Growth

Earnings for OptimizeRx are expected to grow by 17.65% in the coming year, from $0.51 to $0.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptimizeRx is 17.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptimizeRx is 17.97, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 78.05.

Price to Book Value per Share Ratio

OptimizeRx has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.67% of the float of OptimizeRx has been sold short.

Short Interest Ratio / Days to Cover

OptimizeRx has a short interest ratio ("days to cover") of 6.33.

Change versus previous month

Short interest in OptimizeRx has recently increased by 6.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptimizeRx does not currently pay a dividend.

Dividend Growth

OptimizeRx does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for OptimizeRx this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OptimizeRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.50% of the stock of OptimizeRx is held by insiders.

Percentage Held by Institutions

76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/07/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: COMP - SOFTWARE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:OPRX
• CIK: 1448431
• Web: www.optimizerx.com
• Phone: (248) 651-6568
• Fax: 248-453-5529
• Employees: 100
• Year Founded: 2006

Price Target and Rating

• Average Price Target for OptimizeRx: $13.43
• High Price Target: $24.00
• Low Price Target: $7.00
• Potential Upside/Downside: +113.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.35
• Trailing P/E Ratio: 17.97
• Forward P/E Ratio: 12.33
• P/E Growth: N/A
• Net Income: $5.13 million
• Net Margins: 6.37%
• Pretax Margin: 8.92%
• Return on Equity: 10.86%
• Return on Assets: 7.93%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 5.37
• Quick Ratio: 5.37

Sales & Book Value

• Annual Sales: $109.43 million
• Price / Sales: 1.08
• Cash Flow: $1.00 per share
• Price / Cash Flow: 6.29
• Book Value: $6.88 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 18,760,000
• Free Float: 17,358,000
• Market Cap: $118.00 million
• Optionable: Optionable
• Beta: 1.08